178924-20-4

Basic information

• Product Name: 4-cyclohexylthiophene-2-carbaldehyde
• Synonyms: 4-cyclohexylthiophene-2-carbaldehyde
• CAS NO: 178924-20-4
• Molecular Weight: 194.298
• Mol File: 178924-20-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-cyclohexylthiophene-2-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4-cyclohexylthiophene-2-carbaldehyde(178924-20-4)
• EPA Substance Registry System: 4-cyclohexylthiophene-2-carbaldehyde(178924-20-4)

Safety Data

• Hazardous Substances Data: 178924-20-4(Hazardous Substances Data)

Upstream product

• 931-51-1 cyclohexylmagnesiumchloride 
• 68-12-2 N,N-dimethyl-formamide 
• 120659-34-9 3-cyclohexylthiophene 
• 58267-90-6 4-cyclohex-1-enyl-thiophene-2-carbaldehyde 

Downstream Products

• 957206-10-9 4-Cyclohexyl-5-iodothiophene-2-carbaldehyde 

Relevant articles and documents

A diketopyrrolopyrrole-based low bandgap polymer with enhanced photovoltaic performances through backbone twisting

A diketopyrrolopyrrole (DPP)-based π-conjugated polymer is a very promising low band gap electron donor material for polymer solar cells. We have incorporated alkyl groups into the 4-position of the thiophene rings connected to the DPP fragment, which is proven to be beneficial for improving the open-circuit voltage (VOC) and short-circuit current density (JSC). Two DPP-based polymers are synthesized with benzo[1,2-b:4,5-b′]dithiophene (BDT) as the electron-donating segment. Both the polymers show good solubility, slightly wide optical band gaps and deep HOMO energy levels when incorporating the alkyl groups. Heterojunction solar cells are fabricated with polymer:PC71BM as the active layer. VOC and JSC are simultaneously enhanced compared to the device performance of traditional DPP-BDT alternating polymers. A power conversion efficiency (PCE) of 8.11% was obtained, which indicates that rational utilization of backbone torsion is a promising strategy to improve the photovoltaic performance.

HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE

To provide a novel compound which has S1P receptor agonistic activity, exhibits excellent immunosuppressing effect, gives less adverse side effects, and can be orally administered. The invention provides a compound represented by general formula (I) (wherein A is a single bond, -O-, or - CH2-; R1 represents a hydrogen atom or a C1-C6 alkyl group, and V represents any one group selected from among the following groups (1) to (3) : (1) -G1-, (2) -G2-N(R2) -G3-, and (3) a group represented by formula 2, wherein each of Z1 and Z2 represents a hydrogen atom or a C1-C6 alkyl group, Z3 represents a hydrogen or the like, Q represents -CH2-O- or the like, and Y represents a group represented by foumula 3, a salt thereof, or a solvate thereof.